Revvity (RVTY) said Wednesday the US Food and Drug Administration has approved the company's Auto-Pure 2400 liquid handling platform with the T-SPOT.TB diagnostic test for latent tuberculosis.
The Auto-Pure 2400 platform was launched outside the US in 2024, Revvity said.